Treating Aging Before Disease: Where the Research Stands

On September 30, 2026, CNN published “Can aging be treated like a disease? Scientists are starting to find out”, reporting on efforts to measure and target aging biology before disease develops.

Why researchers want to measure aging before disease

The research question starts earlier than a diagnosis. Instead of addressing separate diseases only after they appear, researchers are studying biological changes that might contribute to several conditions. CNN names diabetes, cardiovascular disease and cancer among the diseases this approach might eventually address.

The goal is healthspan: the years lived in good health. That differs from simply extending lifespan. For men concerned about remaining active and independent, the distinction puts the focus on health during those years rather than the total number alone.

Nir Barzilai leads the Institute for Aging Research at Albert Einstein College of Medicine. He explained the field’s rationale to CNN: “Aging has biology. This biology drives diseases.” His argument is that shared biological processes could offer a broader target for prevention than any single disease.

Looking for signals that respond to interventions

CNN describes work involving Daniel Belsky through the Finding Aging Biomarkers by Searching Existing Trials (FAST) project. Belsky is an associate professor of epidemiology at Columbia University’s Mailman School of Public Health and the Robert N. Butler Columbia Aging Center.

FAST collects several kinds of biological information, known as multi-omic data. These include proteins, metabolites and epigenetic marks on white blood cells. Researchers are looking for indicators that respond when an intervention changes something in the body.

The report also describes methyl groups attached to DNA as signals under investigation. These are among the measures researchers are examining beyond chronological age. Age in years provides one description of a person; the project seeks biological information that might help researchers study changes over time.

CNN does not provide a participant count or demographic breakdown for FAST. It also does not report a completed trial duration. The article describes a research program and expert perspectives rather than presenting a single trial with a defined study population.

Why the timeline matters

Belsky told CNN that testing whether an intervention begun at age 40 or 50 prevents chronic disease might require two or three decades of follow-up. Those ages describe a possible trial scenario, not the reported ages of FAST participants.

That timeline explains the interest in earlier biological signals. Researchers want a way to assess whether an intervention is moving in a useful direction before waiting for long-term disease outcomes. Finding such a signal is the measurement task at the center of this work.

How to read the reported physiological findings

The physiological outcomes described in CNN’s report come from animal research. The article presents two findings that help explain why scientists are pursuing this field:

• Slower accumulation of cellular changes associated with aging. CNN describes this in animal research involving interventions that include medicines, exercise and calorie restriction.
• Extended animal lifespans. The report identifies longer life in animal studies as part of the evidence motivating research into aging biology.

These findings address different questions. A change in cellular processes describes something happening within the body. A longer lifespan describes an outcome across the animal’s life. Keeping those outcomes separate helps readers follow what researchers measured rather than treating every positive result as the same kind of benefit.

FAST has a measurement-focused aim: finding indicators that respond to interventions. CNN’s account describes that aim rather than announcing a set of validated markers. The project belongs to the effort to build better tests for future prevention research.

Why a promising field still needs clinical proof

The central human evidence gap is direct. Belsky told CNN: “For humans, we do not yet have clinical trial evidence that intervention on this biology to extend health span is possible.” Animal findings make the idea worth testing, but they do not establish the same benefit in people.

A separate problem concerns biomarkers. Researchers have not established that changing an aging marker leads to a longer healthy lifespan. A more favorable biological-age result should therefore not be read as additional healthy years already gained.

CNN describes the possible use of a biomarker as a surrogate endpoint. This means using a measured signal in place of waiting for a longer-term health outcome. That role requires a reliable predictive link between the signal and the outcome; the report says researchers are still working to establish it.

Institutional activity also needs to be separated from treatment evidence. According to CNN, Mayo Clinic launched a Healthy Longevity Clinic in 2023. Singapore’s National University Health System established a similar program, while Abu Dhabi introduced a licensing framework for Healthy Longevity Medicine Centers in October 2024.

Those developments show that health systems and regulators have taken an interest in longevity medicine. They do not establish that a clinic’s assessment or intervention extends healthspan. The existence of a service answers a different question from whether its claimed benefit has been demonstrated.

The practical habits discussed in the report are not guarantees against disease or aging either. Belsky presents them as available measures that do not require advanced medical innovations. That is a more grounded claim than promising prevention for every person who follows them.

How to keep the research relevant to life after 45

The practical decision is where to place attention now. Belsky pointed readers toward sleep, exercise, diet and community rather than waiting for new longevity drugs or specialist services. He told CNN: “The thing we know works is available in some form to most of us.”

For men in midlife and later life, that places everyday health habits alongside the research frontier without confusing the two. An experimental measurement may matter to scientists designing a trial. A person deciding how to spend time or money needs to ask what the measurement would change in a real health decision.

Keep available habits in the foreground

Sleep belongs in the discussion. Belsky identified it as one of the practical areas available now. In this article’s context, sleep is not a technology or a biological-age score. It is part of the everyday foundation he directs attention toward.

Exercise remains relevant to the goal of staying capable. Men returning to training may care about strength and mobility more than a laboratory result. Everfitguys’s coverage of strength for everyday activity connects with that interest. CNN’s report supports exercise broadly without prescribing a workout schedule or individual training plan.

Diet is another area Belsky names. The practical implication is to keep ordinary nutrition decisions in view when assessing longevity claims. His comments do not turn the animal findings on calorie restriction into instructions for a reader’s own diet.

Community is part of his advice too. Social connection belongs beside the other habits in the report’s practical takeaway. Keeping it in view prevents the healthy-aging discussion from becoming solely about tests, drugs and cellular pathways.

These subjects fit the wider goal of remaining capable through later life. They give the research a human context: the interest is not only in what a test records but also in the health and capability people hope to preserve.

Ask what a longevity claim actually demonstrates

A useful way to assess an offer is to identify the outcome behind its headline. The questions follow directly from the distinctions in CNN’s report:

• Does the evidence concern animals or people?
• Was the measured result a biological marker or a meaningful health outcome?
• Has that marker been shown to predict the claimed benefit?
• Is the offer describing a demonstrated result or a future possibility?

These questions keep the discussion focused on evidence rather than the appeal of the label “longevity.” They also help separate an interesting research tool from a reason to purchase a treatment.

Medical concerns and proposed interventions belong in a discussion with a qualified clinician. That is particularly relevant when a service offers medical treatment under a longevity label. The personal decision involves the proposed intervention and the person’s health, not only the promise attached to a score.

What this changes: this report does not alter current best practices; it reinforces the existing focus on sleep, exercise, diet and social connection while researchers test a different approach to prevention.

How Everfitguys helps

Before paying for a longevity assessment, the practical decision is whether its claims match its evidence, a distinction Everfitguys covers for men in midlife and later life. The publication helps readers sort uncertain healthy aging claims through clear research reporting focused on strength, mobility and mental sharpness, without prescribing personal treatment.

Read the research

Sources

1. Can aging be treated like a disease? Scientists are starting ...
2. Can aging be treated like a disease? Scientists are starting to find out